New capsule aims to improve c. diff treatment by targeting the colon
NCT ID NCT07251127
First seen Dec 12, 2025 · Last updated May 08, 2026 · Updated 22 times
Summary
This study tested a new delayed-release metronidazole capsule designed to deliver the drug directly to the colon, where C. diff infection occurs. The goal is to improve treatment and reduce side effects compared to standard tablets. 18 healthy adults took part to compare how the body absorbs the new capsule versus the regular tablet.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLOSTRIDIUM DIFFICILE INFECTION (CDI) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Veeda Lifesciences
Ahmedabad, Gujarat, India
Conditions
Explore the condition pages connected to this study.